Business Context and Reporting Period
This Form 8-K was filed by Protalix Biotherapeutics, Inc. on August 28, 2014. The report details a significant regulatory milestone regarding the Company's lead product, ELELYSO (taliglucerase alfa).
Key Financial Metrics
This filing is a Current Report regarding a specific event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Regulatory Approval: The U.S. Food and Drug Administration (FDA) approved ELELYSO for injection for pediatric patients.
- Indication Expansion: ELELYSO is now indicated for long-term enzyme replacement therapy (ERT) for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
Outlook, Management Commentary, and Risks
Management announced a conference call scheduled for September 3, 2014, at 8:30 am ET. The call will discuss the pediatric approval and provide updates on ongoing clinical programs PRX-112 and PRX-102. No specific financial guidance, risk factors, or contingencies were detailed in this specific filing text.
Key Facts for Investor Verification
- Confirm the commercial launch timeline for the pediatric indication of ELELYSO.
- Verify the status and expected timelines for the PRX-112 and PRX-102 clinical programs mentioned in the upcoming conference call.
- Review the attached press releases (Exhibits 99.1 and 99.2) for detailed commercial implications.